Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29541506 | 1.00 | LMNA (0.39) | LMNAKDM4EHTTSMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL3582648 | 0.98 | LMNA (0.38) | LMNAKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL6208769 | 0.87 | LMNA (0.37) | LMNAKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL16134092 | 0.84 | LMNA (0.40) | LMNAKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL27752949 | 0.83 | HTT (0.41) | LMNAKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL30346051 | 0.83 | LMNA (0.39) | LMNAKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL3965244 | 0.83 | LMNA (0.39) | LMNAKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL1521589 | 0.83 | HTT (0.51) | LMNAKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL1521487 | 0.82 | TRPM8 (0.38) | LMNAKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL6207973 | 0.80 | HTT (0.41) | LMNAKDM4EHTTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590098-B2 | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same | AXCESO BIOPHARMA CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-4215533-B1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AXCESO BIOPHARMA CO LTD (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-20230348474-A1 | PYRIMIDO PYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | AXCESO BIOPHARMA CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348474-A1 | PYRIMIDO PYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | AXCESO BIOPHARMA CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348474-A1 | PYRIMIDO PYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | AXCESO BIOPHARMA CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| EP-4215533-A1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Axceso Biopharma Co., Ltd. (KR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022060094-A1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 엑세쏘바이오파마 | 2022-03-24 | — | — | WO | disclosed |
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-7655651-B2 | Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080032970-A1 | Amide Derivatives of 7-Amino-3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents | HOFFMANN-LA ROCHE INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032970-A1 | Amide Derivatives of 7-Amino-3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents | HOFFMANN-LA ROCHE INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032970-A1 | Amide Derivatives of 7-Amino-3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents | HOFFMANN-LA ROCHE INC. | 2008-02-07 | — | — | US | disclosed |
| US-20070232611-A1 | Amide Derivatives of 3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCNE AG (CH) | 2007-10-04 | — | — | US | disclosed |
| US-20070232611-A1 | Amide Derivatives of 3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCNE AG (CH) | 2007-10-04 | — | — | US | disclosed |
| US-20070232611-A1 | Amide Derivatives of 3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCNE AG (CH) | 2007-10-04 | — | — | US | disclosed |
| EP-1789417-A1 | AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| EP-1789416-A2 | AMIDE DERIVATIVES OF 3-PHENYL DIHYDROPYRIMIDO[4,5-D]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-la Roche AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006024486-A2 | AMIDE DERIVATIVES OF 3-PHENYL DIHYDROPYRIMIDO[4,5-D]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024487-A1 | AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | LMNA 3483/4885KDM4E 2009/4885HTT 1148/4885 |
| US-20070232611-A1 | Amide Derivatives of 3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents | DPYD, THPO, DHPS | LMNA 4475/4885KDM4E 466/4885HTT 3853/4885 |
| US-20080032970-A1 | Amide Derivatives of 7-Amino-3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents | DPYD, GART, DDC | LMNA 4229/4885KDM4E 346/4885HTT 3902/4885 |
| US-20230348474-A1 | PYRIMIDO PYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PDCD1, PDCD1LG2, CD274 | LMNA 2765/4885KDM4E 913/4885HTT 2120/4885 |
| US-12590098-B2 | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same | PDCD1, CD274, PDCD1LG2 | LMNA 2148/4885KDM4E 334/4885HTT 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.